UK Markets close in 2 hrs 1 min

Infinity Pharmaceuticals, Inc. (INFI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.6915-0.0432 (-5.88%)
At close: 04:00PM EDT
0.7313 +0.04 (+5.76%)
Pre-market: 09:26AM EDT
Sign in to post a message.
  • g
    glenn
    why 8 million shares traded today?
  • T
    Thomas
    Just checked NASDAQ short interest and found that number of shares sold short recently has doubled from 6 months ago. As price of INFI is so low, shorts should be covering, not shorting at such a low price. This could amplify upward movement of stock on any good news.
  • A
    Alfredo
    They put the bonds to the value they want. This company makes zero profits, always closes at a loss and has a CEO earning 1.2 B M per year! The investors only serve to make the good life of these administrators. Incredible who still believes in investments!
  • B
    Bruno
    Infinity is looking Finite being down 11% in the midst of a 3% Nasdaq rally.
  • B
    Bruno
    Infinity Pharmaceuticals stock began the trading year on January 3, 2022 at $2.40 a share. The company stock got caught up in the accelerated deterioration of the Nasdaq in a Bear Market, the Correction or whatever the broader market downward spiral will eventually be defined as in retrospect when the situation is fully understood.
  • T
    Thomas
    Good news. INFI shows 2 members of the board of directors as insider buyers of the stock for a total of 77,000 shares bought during the last 3 months. I think this is the first buying (and no selling) for the past year.
  • A
    Alfredo
    There is nothing legal on Wall Street anymore. It’s all a scam with the Sec accomplice!!
  • A
    Alfredo
    If they don’t put a bomb on wall street that blows up all the computer systems this market scam will never end!
  • C
    Chris
    In order to regain compliance, INFI needs to close above $1 per share for 10 consecutive days in the next 180 days.
  • T
    Thomas
    Interesting that today, June 9, BIB biotech index down over 7% while INFI up over 2%. We'll see in a few months if this meant anything.
  • a
    apling
    I am sick of all the spam on yahoo! I actually try to stay off of the INFI message board now and exclusively use (http://Themaxgains.tech)
  • B
    Bruno
    Let's go INFI
  • A
    Alfredo
    There is no point in investing in a market driven by scammers!
  • S
    Smitty
    Crazy how oversold this thing is. Needs to climb back above $2!!!! Announce a partnership soon please!
  • M
    Mike
    Analyst from JP Morgan asked about finances especially as they are expanding Mario trials. The company again said there is a great appetite out their for partnerships with new experimental drug treatments showing success in phase 2 trials. It seemed there was a real focus they expect to be funded through a partnership. 2nd analyst ( didn't get the company) asked about partnership. Company said trials across multiple cancers offers lot's of opportunities to partnership. 3rd analyst asked about Renal cell trial. Expect more results later this year.
  • g
    glenn
    Please, management, no reverse stock split. It would just accelerate the pace of decline while the market awaits positive trial data. Being delisted from NASDAQ has no meaningful negative impact, imo.
  • M
    Mike
    Earnings call just mentioned exploring potential partnerships this year.
  • M
    Mike
    The most positive takeaway I got from the earnings call was that 6 or 7 different analyst asked questions. The relationship between the company and the analysts was very cordial and respectful. I got the feeling that everyone felt like the company was making progress and good days are coming.
  • M
    Mike
    This is why the share price is down. Although the company explained this didn't apply to them in the earnings call yesterday. People are over reacting.

    The FDA aims to put the PI3K inhibitor drug class under a more stringent regulatory scope as the inhibitor has demonstrated substantial toxicity.
    In nearly all of the randomized clinical trials, patients randomized to the PI3K inhibitor arm experienced increased rates of fatal adverse events (AEs), serious adverse events (SAEs), Grade 3 or greater AEs, and treatment modifications or discontinuation due to AEs.
  • M
    Mike
    The earnings call was good and positive. It's available on the INFI website for I think the next 30 days.